Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

  • receive the eCopy two days prior to the printed edition.
  • can partake in our online MCQs.
  • can enter our online sports quiz.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

Hand osteoarthritis improves with prednisolone

By Mindo - 17th Jul 2019 | 41 views

The results of the low-dose prednisolone in patients with hand osteoarthritis (HOPE) study presented at EULAR 2019 show that low-dose prednisolone significantly improves pain and function in patients with painful hand osteoarthritis.

Treatments are currently limited to topical and oral non-steroidal anti-inflammatory drugs (NSAIDs) to relieve pain. However, studies have shown that synovial inflammation is often present in hand osteoarthritis and it is this inflammation that is a main determinant of pain and radiographic disease progression, identifying synovitis as a possible target of treatment.

While prednisolone has been used in other rheumatic diseases such as rheumatoid arthritis, polymyalgia, lupus and vasculitis for a long time it is currently not recommended in patients with hand osteoarthritis due to a previous lack of evidence. 

The results presented at EULAR demonstrate that prednisolone (10mg) provides a significant improvement in pain with an average -16.5 point difference in VAS finger pain (95% CI; -26.1 to -6.9) and a -3.5 point difference in AUSCAN pain (95%CI; -4.9 to -2.1, p<0.001). In addition, 72 per cent vs 33 per cent of patients treated with prednisolone and placebo respectively were classified as responders using the OMERACT-OARSI responder criteria. Prednisolone was shown to significantly improve function with an adjusted mean between-group difference of -3.7 points in AUSCAN function (p=0.01) and -2.1 points in FIHOA (p=0.03). Significant differences were also shown in SF-36 physical component scale and the VAS patient global assessment. A significant reduction in synovitis was also demonstrated using ultrasound.

The study was a randomised, double-blind, placebo-controlled trial of 92 patients with painful hand osteoarthritis (fulfilling American College of Rheumatology criteria) and signs of synovial inflammation. Eligible patients were randomised to receive prednisolone 10mg daily for six weeks or placebo, followed by a two-week tapering scheme and six weeks without study medication.

After tapering, all between group differences disappeared, and adverse events were mostly mild and comparable between groups.

Leave a Reply

Latest
Latest Issue
medical news
The Medical Independent 19th May 2022

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read